Table 3.
Clinical trials related to rare lung cancers without reported results
| Cancer type | Target(s) | Drug | Combination | Clinical trial (phase) | Treatment line | Status |
|---|---|---|---|---|---|---|
| LASC | EGFR | Almonertinib | No | NCT04354961 (II) | First-line | Not yet recruiting |
| PSC | PD-1 | Camrelizumab | Famitinib | NCT04888429 (II) | NA | Not yet recruiting |
| PD-1 | Toripalimab | Bevacizumab; Nab-paclitaxel; Carboplatin | NCT04725448 (I) | First-line | Recruiting | |
| NMCa | BRD4-BD1/2 | BI 894999 | No | NCT02516553 (Ia/Ib) | NA | Completed |
| HDAC and PI3K | CUDC-907 | No | NCT02307240 (I) | NA | Completed | |
| BET and CBP/p300 | EP31670 | No | NCT05488548 (I) | NA | Not yet recruiting | |
| NSCLC with rare histology | PD-L1 | Atezolizumab | No | NCT03976518 (II) | Beyond first-line | Recruiting |
NA, not available.
a
Midline carcinoma with NUT rearrangement regardless of the primary site.